AU2001273041A1 - Methods for use of delivery composition for expanding, activating, committing ormobilizing one or more pluripotent, self-renewing and committed stem cells - Google Patents

Methods for use of delivery composition for expanding, activating, committing ormobilizing one or more pluripotent, self-renewing and committed stem cells

Info

Publication number
AU2001273041A1
AU2001273041A1 AU2001273041A AU7304101A AU2001273041A1 AU 2001273041 A1 AU2001273041 A1 AU 2001273041A1 AU 2001273041 A AU2001273041 A AU 2001273041A AU 7304101 A AU7304101 A AU 7304101A AU 2001273041 A1 AU2001273041 A1 AU 2001273041A1
Authority
AU
Australia
Prior art keywords
ormobilizing
committing
renewing
pluripotent
expanding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001273041A
Inventor
Jeffrey B. Etter
Gary J Rosenthal
James E Talmadge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RxKinetix Inc
University of Nebraska
Original Assignee
RxKinetix Inc
University of Nebraska
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RxKinetix Inc, University of Nebraska filed Critical RxKinetix Inc
Publication of AU2001273041A1 publication Critical patent/AU2001273041A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2046—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
AU2001273041A 2000-06-26 2001-06-26 Methods for use of delivery composition for expanding, activating, committing ormobilizing one or more pluripotent, self-renewing and committed stem cells Abandoned AU2001273041A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21429800P 2000-06-26 2000-06-26
US60214298 2000-06-26
US27489101P 2001-03-09 2001-03-09
US60274891 2001-03-09
PCT/US2001/020544 WO2002000173A2 (en) 2000-06-26 2001-06-26 Methods for use of delivery composition for expanding, activating, committing or mobilizing one or more pluripotent, self-renewing and committed stem cells

Publications (1)

Publication Number Publication Date
AU2001273041A1 true AU2001273041A1 (en) 2002-01-08

Family

ID=26908857

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001273041A Abandoned AU2001273041A1 (en) 2000-06-26 2001-06-26 Methods for use of delivery composition for expanding, activating, committing ormobilizing one or more pluripotent, self-renewing and committed stem cells
AU2001273034A Abandoned AU2001273034A1 (en) 2000-06-26 2001-06-26 Composition for delivery of hematopoietic growth factor

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2001273034A Abandoned AU2001273034A1 (en) 2000-06-26 2001-06-26 Composition for delivery of hematopoietic growth factor

Country Status (6)

Country Link
US (6) US6875441B2 (en)
EP (1) EP1351696A4 (en)
AU (2) AU2001273041A1 (en)
BR (1) BR0111948A (en)
MX (1) MXPA03000190A (en)
WO (2) WO2002000173A2 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7361330B2 (en) * 1995-10-04 2008-04-22 Immunex Corporation Methods of using flt3-ligand in the treatment of fibrosarcoma
AU2001276831A1 (en) * 2000-06-22 2002-01-02 Rxkinetix, Inc. Delivery vehicle composition and methods for delivering antigens and other drugs
WO2002000173A2 (en) * 2000-06-26 2002-01-03 Rxkinetix, Inc. Methods for use of delivery composition for expanding, activating, committing or mobilizing one or more pluripotent, self-renewing and committed stem cells
US6702744B2 (en) 2001-06-20 2004-03-09 Advanced Cardiovascular Systems, Inc. Agents that stimulate therapeutic angiogenesis and techniques and devices that enable their delivery
EP1441748A4 (en) * 2001-10-16 2007-07-11 Rxkinetix Inc High-concentration protein formulations and method of manufacture
US8608661B1 (en) 2001-11-30 2013-12-17 Advanced Cardiovascular Systems, Inc. Method for intravascular delivery of a treatment agent beyond a blood vessel wall
US7361368B2 (en) * 2002-06-28 2008-04-22 Advanced Cardiovascular Systems, Inc. Device and method for combining a treatment agent and a gel
SI21258A (en) * 2002-07-17 2004-02-29 LEK farmacevtska dru�ba d.d. Stable pharmaceutical preparation containing erythropoietin and poloxamer polyol
US8821473B2 (en) 2003-04-15 2014-09-02 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
US7641643B2 (en) 2003-04-15 2010-01-05 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
US8038991B1 (en) 2003-04-15 2011-10-18 Abbott Cardiovascular Systems Inc. High-viscosity hyaluronic acid compositions to treat myocardial conditions
US20050123550A1 (en) * 2003-05-12 2005-06-09 Laurent Philippe E. Molecules enhancing dermal delivery of influenza vaccines
US7588774B2 (en) 2003-05-12 2009-09-15 Becton, Dickinson And Company Molecules enhancing dermal delivery of influenza vaccines
US8071580B2 (en) * 2004-10-01 2011-12-06 Prometic Biosciences Inc. Medium-chain length fatty alcohols as stimulators of hematopoiesis
US20080125745A1 (en) 2005-04-19 2008-05-29 Shubhayu Basu Methods and compositions for treating post-cardial infarction damage
US8187621B2 (en) 2005-04-19 2012-05-29 Advanced Cardiovascular Systems, Inc. Methods and compositions for treating post-myocardial infarction damage
US8303972B2 (en) 2005-04-19 2012-11-06 Advanced Cardiovascular Systems, Inc. Hydrogel bioscaffoldings and biomedical device coatings
US8828433B2 (en) * 2005-04-19 2014-09-09 Advanced Cardiovascular Systems, Inc. Hydrogel bioscaffoldings and biomedical device coatings
US9539410B2 (en) 2005-04-19 2017-01-10 Abbott Cardiovascular Systems Inc. Methods and compositions for treating post-cardial infarction damage
NZ564843A (en) * 2005-08-03 2012-05-25 Immunogen Inc Immunoconjugate formulations comprising an immunoconjugate and an excipient in a buffered aqueous solution
US7732190B2 (en) 2006-07-31 2010-06-08 Advanced Cardiovascular Systems, Inc. Modified two-component gelation systems, methods of use and methods of manufacture
US9242005B1 (en) 2006-08-21 2016-01-26 Abbott Cardiovascular Systems Inc. Pro-healing agent formulation compositions, methods and treatments
US9005672B2 (en) 2006-11-17 2015-04-14 Abbott Cardiovascular Systems Inc. Methods of modifying myocardial infarction expansion
US8741326B2 (en) 2006-11-17 2014-06-03 Abbott Cardiovascular Systems Inc. Modified two-component gelation systems, methods of use and methods of manufacture
US8192760B2 (en) 2006-12-04 2012-06-05 Abbott Cardiovascular Systems Inc. Methods and compositions for treating tissue using silk proteins
KR20120100962A (en) 2009-10-02 2012-09-12 박스터 헬쓰케어 에스.에이. Hematopoietic stem cells for use in the treatment of a kidney injury
US9677042B2 (en) 2010-10-08 2017-06-13 Terumo Bct, Inc. Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
US20130216495A1 (en) 2012-02-21 2013-08-22 Baxter Healthcare Sa Pharmaceutical composition comprising cd34+ cells
EP3068867B1 (en) 2013-11-16 2018-04-18 Terumo BCT, Inc. Expanding cells in a bioreactor
US10052283B2 (en) * 2014-02-20 2018-08-21 Gwangju Institute Of Science And Technology Composition for forming pluronic-based hydrogel with improved stability
JP6783143B2 (en) 2014-03-25 2020-11-11 テルモ ビーシーティー、インコーポレーテッド Passive replenishment of medium
WO2016049421A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled feed
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
JP7393945B2 (en) 2017-03-31 2023-12-07 テルモ ビーシーティー、インコーポレーテッド cell proliferation

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69033584T2 (en) 1989-10-16 2001-03-08 Amgen Inc Stem cell factor
US5292516A (en) * 1990-05-01 1994-03-08 Mediventures, Inc. Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers
US5346703A (en) 1990-08-07 1994-09-13 Mediventures, Inc. Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
EP0551626A1 (en) 1991-12-19 1993-07-21 LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. Thermoreversible gel as a liquid pharmaceutical carrier for a galenic formulation
CA2194228C (en) * 1994-07-07 2001-04-03 Virginia Lee Price Fusion proteins comprising gm-csf and antigens and their expression in yeast
US5840338A (en) * 1994-07-18 1998-11-24 Roos; Eric J. Loading of biologically active solutes into polymer gels
US5939485A (en) * 1995-06-19 1999-08-17 Medlogic Global Corporation Responsive polymer networks and methods of their use
US5728581A (en) * 1995-06-07 1998-03-17 Systemix, Inc. Method of expanding hematopoietic stem cells, reagents and bioreactors for use therein
US5702717A (en) * 1995-10-25 1997-12-30 Macromed, Inc. Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
US5902110A (en) * 1995-12-18 1999-05-11 The Block Drug Company Bone regeneration
US6017527A (en) * 1996-07-10 2000-01-25 Immunex Corporation Activated dendritic cells and methods for their activation
US5861174A (en) 1996-07-12 1999-01-19 University Technology Corporation Temperature sensitive gel for sustained delivery of protein drugs
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
US6043389A (en) 1997-03-11 2000-03-28 Mor Research Applications, Ltd. Hydroxy and ether-containing oxyalkylene esters and uses thereof
US5980912A (en) 1997-03-25 1999-11-09 Zonagen, Inc. Chitosan induced immunopotentiation
US6054315A (en) * 1997-09-05 2000-04-25 The Board Of Regents Of The University Of Oklahoma Method for making activated neutrophils recognizable to macrophages
US6004573A (en) * 1997-10-03 1999-12-21 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
NZ505324A (en) * 1997-12-22 2002-11-26 Human Genome Sciences Inc Liquid and lyophilised KGF-2 polypeptide formulations used to accelerate soft tissue growth or regeneration
GB9801061D0 (en) 1998-01-20 1998-03-18 Univ Nottingham Patterning technique
CA2305787A1 (en) * 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
US6280742B1 (en) 1998-06-17 2001-08-28 Zonagen, Inc. Methods and materials for the treatment of prostatic carcinoma
EP1137373A4 (en) * 1998-12-04 2004-05-19 Chandrashekhar P Pathak Biocompatible crosslinked polymers
US6451346B1 (en) * 1998-12-23 2002-09-17 Amgen Inc Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
ES2311451T3 (en) 1999-03-24 2009-02-16 The Secretary Of State For Defence POLICATION CARBOHYDRATES AS IMMUESTIMULANTS IN VACCINES.
CA2380912A1 (en) 1999-08-16 2001-02-22 Christopher Allen Seid Methods and materials for the treatment of prostatic carcinoma
WO2002000173A2 (en) * 2000-06-26 2002-01-03 Rxkinetix, Inc. Methods for use of delivery composition for expanding, activating, committing or mobilizing one or more pluripotent, self-renewing and committed stem cells

Also Published As

Publication number Publication date
US20050147684A1 (en) 2005-07-07
MXPA03000190A (en) 2004-09-13
US20090232835A1 (en) 2009-09-17
WO2002000171A2 (en) 2002-01-03
EP1351696A2 (en) 2003-10-15
US20020102272A1 (en) 2002-08-01
US6875441B2 (en) 2005-04-05
WO2002000173A3 (en) 2002-06-13
US6649189B2 (en) 2003-11-18
US20020028515A1 (en) 2002-03-07
US20050147682A1 (en) 2005-07-07
EP1351696A4 (en) 2004-04-14
WO2002000173A2 (en) 2002-01-03
WO2002000171A3 (en) 2003-07-17
US20050147683A1 (en) 2005-07-07
AU2001273034A1 (en) 2002-01-08
BR0111948A (en) 2004-08-24

Similar Documents

Publication Publication Date Title
AU2001273041A1 (en) Methods for use of delivery composition for expanding, activating, committing ormobilizing one or more pluripotent, self-renewing and committed stem cells
AU2001294876A1 (en) Direct growth of nanotubes, and their use in nanotweezers
AU2002319780A1 (en) Alternative compositions and methods for the culture of stem cells
EP1562636A4 (en) Mesenchymal stem cells and methods of use thereof
AU2001245928A1 (en) Electrolyzer and method of using the same
AU2001296512A1 (en) Methods and devices for improving mitral valve function
AU2001278877A1 (en) A composition for the delivery of live cells and methods of use
AU2002211389A1 (en) Microfluidic devices and methods of use
AU2001280597A1 (en) Compositions for sustained release of analgesic agents, and methods of making and using the same
AU1939801A (en) In situ bioreactors and methods of use thereof
AU6340600A (en) Telomerase inhibitors and methods of their use
AU2002241508A1 (en) Membrane derived caspase-3, compositions comprising the same and methods of use therefor
AU2002213346A1 (en) Osteopontin-coated surfaces and methods of use
AU2001288972A1 (en) Antipsychotic sulfonamide-heterocycles, and methods of use thereof
AU2002314887A1 (en) Gads as modifiers of the p53 pathway and methods of use
AU2003240628A1 (en) Method for establishing and expanding multipotent stem cells
AU2001255696A1 (en) Telomerase inhibitors and methods of their use
AU2002363938A1 (en) Methods and use of motoneuronotropic factors
AU2003294575A1 (en) Implant anchor and methods of use
AU2003302574A1 (en) Method of extract composition control in peat extraction, peat extract, and use of peat extract
AU2001217686A1 (en) Method of establishing cultures of human dendritic cells and use thereof
AU2001261496A1 (en) Luxo-sigma54 interactions and methods of use
AU2002246585A1 (en) Plant promoters, and methods of use
AU2003279800A1 (en) Sulfatases and methods of use thereof
AU2002352696A1 (en) Cell substrates and methods of use thereof